anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Anthracyclines are broad-spectrum anticancer drugs, but their clinical use is limited due to their severe cardiotoxicity. Anthracycline-induced cardiotoxicity (AIC) remains a significant cause of heart disease-related mortality in many cancer survivors. The underlying mechanisms of AIC have been explored over the past few decades. Reactive oxygen species and drug-induced inhibition of topoisomerase II beta are well-studied mechanisms, with mitochondria being a prominently investigated organelle. Emerging mechanisms such as ferroptosis, Ca2+ overload, autophagy and inflammation mediators have been implicated in recent years. In this review, our goal is to summarize and update the roles of various mechanisms in AIC, focusing on different cellular levels and further explore promising therapeutic approaches targeting these organelles or pathways.
Hypertension stands out as a substantial independent risk factor in the progression of chronic kidney disease; however, the exact pathological mechanisms remain elusive. Our preliminary studies find that Wnt/β-catenin control renin-angiotensin system (RAS) expression, thus playing an important role in the pathogenesis of hypertension and renal fibrosis. As an integral component of the RAS, the (pro)renin receptor (PRR) plays a crucial role in the activation of the RAS and hypertension. Recent studies suggest a reciprocal relationship between PRR and Wnt/β-catenin signaling, potentially contributing to hypertensive renal fibrosis development. To assess the role of PRR in mediating hypertensive nephropathy, we manipulated this signaling by over expression of PRR ligand or blockade of PRR by siPRR. In vivo, PRR induction promoted hypertension, proteinuria, renal fibrosis, inflammatory response and β-catenin activation in Ang II induced hypertension mice. Conversely, blockade of PRR inhibited Ang II mediated hypertension, renal fibrosis and inflammation. In vitro, PRR over expression renal tubular cells exacerbated the Ang II induced fibrotic response and inflammation. Moreover, PRR was upregulated in hypertensive nephropathy patients, and correlated with renal function and renal fibrosis. These results indicate that PRR interact with Wnt/β-catenin signaling promote the progression of hypertensive nephropathy. PRR could be served as a biomarker for the diagnosis and treatment of hypertensive renal fibrosis.
An oral particle structure for female health care is provided. The oral particle structure for female health care includes a bacteria core layer, a moisture-retaining structure layer, a temperature and pressure resistant structure layer, an air barrier structure layer, an anti-adhesion structure layer, and a damp-proof structure layer. The bacteria core layer includes a bacteria strain particle. The moisture-retaining structure layer covers the bacteria core layer. The temperature and pressure resistant structure layer covers the moisture-retaining structure layer. The air barrier structure layer covers the temperature and pressure resistant structure layer. The anti-adhesion structure layer covers the air barrier structure layer, and the damp-proof structure layer covers the anti-adhesion structure layer. The oral particle structure for female health care may prevent the bacteria core layer from losing activity during the subsequent freeze-drying and storage processes and increase the survival rate.
Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
1377979 Water fluoridation and purification: hydrated aluminium sulphate composition BOLIDEN AB 26 Nov 1971 [30 Nov 1970] 55136/71 Headings C1A and C1C A water-fluorinating and -purifying composition comprises aluminium sulphate hydrate in powder or granulate form and homogeneously distributed through the hydrated sulphate a fluorine compound in an amount corresponding to 0À5-5À0% by weight of fluorine based on the total weight of the hydrated sulphate and fluorine compound, the fluorine compound arising from the addition of a compound selected from NaF, HF, H 2 SiF 6 , Na 2 SiF 6 , (NH 4 ) 2 SiF 6  and Na 3 AlF 6  to the aluminium sulphate hydrate, the latter in the form of an aqueous solution or melt. The composition may be prepared by a process comprising forming an aqueous solution or melt of aluminium sulphate sulphate, adding an appropriate amount of the selected fluoride and crystallizing out an aluminium sulphate hydrate having a fluorine compound homogeneously distributed therethrough. The aqueous solution of aluminium sulphate may be prepared by digestion with sulphuric acid of an aluminium-containing material, e.g. aluminium hydroxide or a clay or bauxite; the solution may be filtered and concentrated to an Al 2 O 3  content of 14-18% before addition of the fluoride. Raw water is treated by adding thereto an amount of the composition which is preferably such as to provide 15-150 mg. of the sulphate hydrate and fluorine compound per litre of water treated and removing the resulting flocks carrying down impurities, giving a fluoridated drinking water. When the raw water already contains a high fluorine content, say 4%, the flocculation brings down some of the fluorine providing a safe-guard against over-fluoridation.
This will be a cross-over study where participants with OI will be randomized to initially receive midodrine or placebo then crossed over to the opposite treatment after three weeks (2 weeks on midodrine or placebo plus one week wash out period). The control group will consist of participants with OH and PD being treated with midodrine. Basic demographic data including will be collected from the medical record of each participant after consent. At each study visit, each participant will undergo traditional measurement of blood pressure and heart rate as well as measurement of beat-to-beat blood pressure and heart rate using CNAP™ during valsalva maneuver and in response to standing for 5 minutes after sitting. Symptoms of orthostatic intolerance will be measured during the study visit using Domain 1 of the Non-Motor Symptoms Scale for Parkinson's Disease (NMSS). At the initial study visit, participants will also be administered first dose of midodrine or placebo. Supine sitting, and standing systolic and diastolic blood pressure and pulse rates will be measured immediately before and 1 hour after the administration of drug or placebo. This blood pressure monitoring process will take place at each of the four study visits.
Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including enalaprilat injection) may be subject to a variety of adverse reactions, some of them serious. 

Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalaprilat. This may occur at any time during treatment. In such cases, enalaprilat injection should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS). 

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS). 

Anaphylactoid reactions during desensitization: Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge. 

Anaphylactoid reactions during membrane exposure: Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.
A composition comprising the extract of black ginseng leaf having higher content of saponins than ginseng root is provided to improve anti-cancer effects as compared to products prepared with ginseng root through 9-time steaming and drying method or high temperature high pressure method. An anti-cancer composition comprises the extract of black ginseng leaf having water content of 14% or less which is prepared by washing 4-6 year-old ginseng leaves with a sonicator at 15 minutes in three times, and drying them at 40-60 deg. C for 20-28 hours, pulverizing the dried ginseng leaves and steaming them in a steamer at 85-105 deg. C for 2-4 hours, drying the steamed ginseng leaves at 50-70 deg. C for 9-15 hours, and repeating the washing, drying, steaming and drying steps in 9 times, and is a pharmaceutical or health food composition. Further, the extract is extracted by a solvent selected from water, C1 to 4 lower alcohol or a mixture thereof.
We propose to invite 80 participants who have already completed the 2 doses vaccination of CoronaVac with low level of neutralizing antibody at 1-month post-vaccination to join this additional study. They will be randomized to receive a booster dose of Coronavac or BionTech in equal numbers (n=40 each group).
The intervention will consist of a multicomponent exercise training programme, which will be composed of supervised progressive resistance exercise training, balance-training, strength-training and walking for 4 consecutive days. During the training period, patients will be trained in 30 min sessions daily.
The invention relates to the technical field of vaccines, in particular to a porcine mycoplasma pneumonia and porcine circovirus type 2 recombinant protein, a bivalent genetic engineering vaccine prepared from the same and application thereof. A mycoplasma hyopneumoniae and porcine circovirus type 2 bivalent genetic engineering vaccine is characterized by comprising Mhp P97R1-P46-P42 recombinant protein and PCV2 Cap recombinant protein. The sequence of the encoding gene of the Mhp P97R1-P46-P42 recombinant protein is shown in SEQ ID NO. 1; the sequence of the encoding gene of the PCV2 Cap recombinant protein is shown in SEQ ID NO. 2. The bivalent genetic engineering vaccine can effectively prevent and control the mycoplasma hyopneumoniae and the porcine circovirus type 2, and has good application prospect.
BACKGROUND: The role of histone methyltransferase SETDB1 in renal ischemia-reperfusion (I/R) injury has not been explored yet. This study aims to investigate the potential mechanism of SETDB1 in regulating renal I/R injury and its impact on mitochondrial damage and oxidative stress.
METHODS: The in vivo model of renal I/R in mice and the in vitro model of hypoxia/reoxygenation (H/R) in human renal tubular epithelial cells (HK-2) were constructed to detect the expression of SETDB1. Next, the specific inhibitor (R,R)-59 and knockdown viruses were used to inhibit SETDB1 and verify its effects on mitochondrial damage and oxidative stress. Chromatin immunoprecipitation (ChIP) and coimmunoprecipitation (CoIP) were implemented to explore the in-depth mechanism of SETDB1 regulating renal I/R injury.
RESULTS: The study found that SETDB1 had a regulatory role in mitochondrial damage and oxidative stress during renal I/R injury. Notably, SESN2 was identified as a target of SETDB1, and its expression was under the influence of SETDB1. Besides, SESN2 mediated the regulation of SETDB1 on renal I/R injury. Through deeper mechanistic studies, we uncovered that SETDB1 collaborates with heterochromatin HP1β, facilitating the labeling of H3K9me3 on the SESN2 promoter and impeding SESN2 expression.
CONCLUSIONS: The SETDB1/HP1β-SESN2 axis emerges as a potential therapeutic strategy for mitigating renal I/R injury.
FIELD: microbiological methods. SUBSTANCE: invention, in particular, relates to variety of cells circulating in blood or found in marrow. Physiologically compatible solution for cryogenic storage contains innocuous components: glycerol, alkali metal chloride, monosaccharide, serum albumin. Proportions of components are given. Unfrozen target cells are introduced into recipient with no separation of target cells and cryogenic storage solution. Solution is easy to prepare and is capable of providing comparable levels of in vivo and in vitro cell viability under cryogenic conditions. EFFECT: achieved optimal viability of cells and possibility of their long-term storage. 32 cl
Stroke is a prevalent medical condition, primarily affecting individuals aged 65 and older. However, it can also strike young people and even children and ranks as the second leading cause of non-traumatic disability and cognitive impairment among adults. Stroke can lead to a range of physical, sensory, and cognitive deficits and impairments in psychosocial functioning. One of the most significant challenges faced by stroke survivors is cognitive impairment. The prevalence of cognitive impairment following a stroke varies widely, ranging from 20% to 80%, and it is influenced by factors such as geographical location, ethnicity, and diagnostic criteria. Stroke can disrupt various cognitive functions, including information processing, memory, planning, problem-solving, spatial awareness, apraxia, motor control, spatial perception, confusion, denial (anosognosia), and object recognition issues (agnosia). The literature reports that 30% of stroke patients experience functional limitations related to balance, speech, and cognitive issues. Particularly, more than half of stroke patients over the age of 65 experience hemiparesis, and around 30% require assistance for walking. Chronic stroke can also lead to balance and mobility problems, affecting daily life activities and significantly impacting the patient's overall quality of life.

There is a growing need for improvements in the post-stroke experience and long-term care for stroke patients. In this context, rehabilitation interventions play a vital role. Rehabilitation interventions aim to prevent complications, reduce neurological deficits, maximize functional capacity, and ultimately promote personal autonomy and social integration. Dance intervention, as part of the rehabilitation process, is recognized as an effective approach to addressing chronic stroke-related motor disorders, positively impacting post-stroke health, and promoting socialization. Dance, characterized by rhythmic body movements to music, serves as a form of artistic or emotional expression and can be performed individually, in pairs, or in groups. It is a multifaceted activity that engages both physical and cognitive abilities. Dance has been found to have positive effects on emotions, sensory stimulation, motor coordination, social interaction, perception, executive functions, and memory. Literature suggests that dance intervention helps to improve both the physical and cognitive impairments of stroke patients through promoting interpersonal harmony and multiple stimulations, and therefore its use is recommended to enhance the cognitive and physical functions of chronic stroke patients. In light of this information, this single-blind, randomized, controlled study aims to investigate the impact of dance intervention on cognitive functions and quality of life among chronic stroke patients.
The invention relates to a patch for treating infantile diarrhea. The patch comprises a blank plaster stick with a leakage-proof ring and unguent which the interior of the leakage-proof ring is coated with. The unguent is composed of effective components, vitamin E and substrates. The effective components are prepared from, by weight, 20.5-25.2% of volatile oil from amomum villosum, 20.7-25.2% of volatile oil from rhizoma atractylodis, 17.0-21.2% of volatile oil from cinnamon and 29.1-35.4% of volatile oil from cloves. Volatile oil forming the effective components is prepared according to the following method that amomum villosum, rhizoma atractylodis, cinnamon and clove medicinal material powder is obtained, water with the amount 15 times that of the amomum villosum, rhizoma atractylodis, cinnamon and clove medicinal material powder is added into the amomum villosum, rhizoma atractylodis, cinnamon and clove medicinal material powder, soaking is performed for 30 min, backflow extraction is performed at the temperature of 100 DEG C, volatile oil is collected, and the volatile oil from amomum villosum, the volatile oil from rhizoma atractylodis, the volatile oil from cinnamon and the volatile oil from cloves are respectively obtained. The using amount of the vitamin E is 1.5-3.0% of the effective components. The substrates are wool grease. The medicine flavor of the patch is slight, the stabilizing effect is good, and the curative effect is remarkable.
PURPOSE:To provide the titled extremely safe non-irritant and non-eruptive plaster for the transcutaneous administration of a physiologically active substance and containing a fatty acid ester, a natural gum and a water-absorbing polymer as essential components of plaster. CONSTITUTION:The objective plaster for transcutaneous administration can be produced by using a plaster component containing (A) a fatty acid ester (e.g. isopropyl myristate, butyl stearate, etc.), (B) a natural gum (e.g. gum arabic, gum guaiac, etc.) and (C) a water-absorbing polymer (absorbing 10 times weight of water to effect the dissolution, gelation or swelling; e.g. polyacrylic acid) at ratios of (1-5)/(2-5)/(2-10) and, if necessary, adding a drug component to the plaster component. The total amount of the above three components in the base is 8-45wt%. EFFECT:Side effects such as eruption caused by stuffiness, perspiration, etc., can be suppressed and the plaster can be peeled off from the skin with little pain from pulling of hair.
Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
PURPOSE: Spinal osteotomies are often essential in the treatment of congenital scoliosis. Risk factors for bleeding in these patients needing extracavitatory approaches, especially hidden blood loss, are sparsely investigated. We aimed to investigate the bleeding characteristics and hidden blood loss in paediatric patients undergoing spinal osteotomies for congenital scoliosis.
METHODS: A retrospective analysis identified all patients with congenital scoliosis were retrospectively identified from the prospectively collected spine register from 2010 to 2022. Operative technique, perioperative laboratory results and imaging studies were extracted. The primary outcome was total blood loss including intraoperative, drain output and hidden blood loss.
RESULTS: Fifty-seven children (32 boys) with a mean age of 8.3 years underwent spinal osteotomy for congenital scoliosis. Posterolateral hemivertebrectomy was sufficient in 34 (59%) patients, while vertebral column resection (VCR) was required in 23 patients. Total bleeding averaged 792 (523) ml accounting for 42% of the estimated blood volume. Hidden blood loss accounted for 40% of total bleeding and 21% of estimated blood volume with a mean of 317 (256) ml. VCR was associated with greater intraoperative and total bleeding than hemivertebrectomies (p = 0.001 and 0.007, respectively). After adjusting for patient weight and fusion levels, hidden blood loss was larger in hemivertebrectomies (4.18 vs. 1.77 ml/kg/fused level, p = 0.049). In multivariable analysis, intraoperative blood loss was inversely correlated with preoperative erythrocyte levels. Younger age was associated with significantly greater drain, hidden and total blood loss.
CONCLUSION: Hidden blood loss constitutes a significant portion (40%) of total bleeding in congenital scoliosis surgery. Younger age is a risk factor for bleeding and the hidden blood loss should be taken into consideration in their perioperative management.
The invention discloses composite materials, comprising an inorganic nonmetallic mineral as a support and a nanotitania layer loaded on the support, wherein the layer is comprised of a plurality of titania nanospheres, and the titania nanosphere is comprised of a plurality of nanotitania single particles. The invention also discloses composite materials further comprising one or more functional layers loaded on the nanotitania layer. The above composite materials may not only take advantage of the high refractive index and the high covering power of the nanotitania layer, but also make use of the good photocatalytic activity of the small single nanoparticles. Furthermore, the composite materials can be more readily coated by other functional layer(s) to prepare functionally strengthened or multi-functional composite materials. The invention also discloses methods for preparing the composite materials. The composite materials may be used as an additive with good compatibility in various industrial fields.
Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
Building on the successes of a communal, relationship based approach to Aboriginal youth mentoring in an after school physical activity program (AYMP), the investigators are evaluating a peer-led approach for diabetes prevention. High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Our primary goal is to determine the health benefits of AYMP; guided by our youth mentors and community advisors, the investigators will also develop a number of research questions that will help us to better understand the social, emotional, physical and spiritual outcomes of the peer-led mentor program. To answer these questions, the investigators will train community members in both qualitative and quantitative methods. The quantitative outcomes of this study include physical activity, waist circumference, obesity rates, and self-esteem. Qualitative methods may include photovoice and focus group interviews. All of these will be used to assess the social determinants of health and contextual features of the program.